OOIR: Observatory of International Research

Papers

(The H4-Index of Pharmacology & Therapeutics is 62. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Editorial Board	351
Adenosine receptor signalling as a driver of pulmonary fibrosis	345
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	318
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	271
The role of macrophages in asthma-related fibrosis and remodelling	229
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	227
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	207
Potential neonatal toxicity of new psychoactive substances	205
Unfolded protein responses: Dynamic machinery in wound healing	199
Inflammation, lipids, and pain in vulvar disease	186
Matrikines in the skin: Origin, effects, and therapeutic potential	183
Treatment strategies for leptomeningeal disease in patients with breast cancer	172
Endothelial dysfunction as a complication of anti-cancer therapy	153
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	143
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	143
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	140
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	136
Non-canonical G protein signaling	134
Collateral lethality: A unique type of synthetic lethality in cancers	129
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	128
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	119
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	117
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	115
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	114
Contribution of non-selective membrane channels and receptors in epilepsy	114

Management of drug-resistant hypertension as a heterogeneous disorder	106
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	104
Cell-based therapies for vascular regeneration: Past, present and future	100
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	100
TAAR1 as an emerging target for the treatment of psychiatric disorders	99
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	97
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	94
TLR4 biased small molecule modulators	93
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	92
Dysregulation of metabolic pathways in pulmonary fibrosis	91
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	91
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	91
Boron in cancer therapeutics: An overview	91
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	90
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	89
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	88
Review: Sex-related differences in the treatment of cardiac arrhythmia	87
Editorial Board	85
Pharmacological treatment of cardiogenic shock – A state of the art review	84
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	81
Natural products that alleviate depression: The putative role of autophagy	81
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	79
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	78
PGRMC1: An enigmatic heme-binding protein	78
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	78
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	74
Bispecific antibodies for the treatment of neuroblastoma	73
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	72
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	71
Wnt signaling: A prospective therapeutic target for chronic pain	69
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	69
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	67
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	66
DNA methylation in cell plasticity and malignant transformation in liver diseases	66
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	66
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	65
Stabilizing the neural barrier – A novel approach in pain therapy	65
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	62
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	62
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	62
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	62